BioNTech SE (NASDAQ:BNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of BioNTech SE (NASDAQ:BNTX) have received a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $109.09.

A number of equities research analysts have weighed in on BNTX shares. JPMorgan Chase & Co. lowered their price objective on BioNTech from $94.00 to $91.00 and set an “underweight” rating for the company in a research note on Thursday, August 15th. TD Cowen decreased their price target on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Deutsche Bank Aktiengesellschaft raised shares of BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a report on Wednesday, August 7th. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Finally, HSBC raised shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd.

Hedge Funds Weigh In On BioNTech

Several institutional investors have recently made changes to their positions in BNTX. Dynamic Technology Lab Private Ltd grew its position in shares of BioNTech by 2.5% during the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock worth $492,000 after acquiring an additional 116 shares during the last quarter. Covestor Ltd grew its position in BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares during the period. Arlington Capital Management Inc. increased its stake in shares of BioNTech by 10.0% in the first quarter. Arlington Capital Management Inc. now owns 2,200 shares of the company’s stock valued at $203,000 after purchasing an additional 200 shares during the period. Finally, Midwest Professional Planners LTD. raised its holdings in shares of BioNTech by 7.2% during the first quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after buying an additional 212 shares during the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Trading Up 5.8 %

BNTX opened at $105.00 on Friday. The firm has a market capitalization of $24.96 billion, a P/E ratio of 210.00 and a beta of 0.23. The firm’s 50 day moving average is $86.41 and its 200-day moving average is $89.48. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. BioNTech has a 52-week low of $76.53 and a 52-week high of $117.98.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business’s quarterly revenue was down 23.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.86) EPS. Analysts expect that BioNTech will post -2.8 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.